Drug makers & biotechDrug and biotech companies, with their PACs and trade groups. Pharmacies and distributors are under Other health companies.Business › Health
PAC (qualified)Lobbyist/registrant PACCorporationFoster City, CaliforniaActive
Gilead Sciences Inc lobbied on 7 issues. See lobbying
Its wordsWhat does this committee say it is for?
No published list of positions
This committee’s site publishes no list of positions we could read, and we found no statement of why it exists. We do not write one for it.
Who it gives toWhich candidates and committees get its money?
Each part reads different filings, so counts and totals can differ.
Party support distribution$558.5K to 167 candidates
Direct PAC contributions and independent expenditures explicitly reported as support, by the party of the candidate they went to.
For candidates $558,500
Democratic 42%
Republican 42%
Other or unresolved 16%
Support by the party of the candidate
Party of the candidate
Candidates
Direct
Independent
Amount
Share
Democratic
60
$234,500
$0
$234,500
42%
Republican
81
$234,000
$0
$234,000
42%
Other or unresolved
26
$90,000
$0
$90,000
16%
Shown support
167
$558,500
$0
$558,500
100%
Contributions are reported money, not endorsements; a PAC giving to both parties is common.
Who this PAC gave to$787,000 in 377 payments
Every contribution on line 23 of the committee’s own Schedule B, which is the filing its summary totals are built from. That line covers federal candidates, party committees and other political committees alike, so a super PAC funding other super PACs appears here rather than under candidate giving.
By recipient
Line 23 contributions by kind and party of recipient
Recipient
Count
Amount
Democratic candidates
61
$237K · 30%
Republican candidates
79
$229K · 29%
Other or unresolved candidates
28
$95K · 12%
Other PACs and committees
43
$236K · 30%
All recipients
211
$797K
By the candidate’s state
Contributions to candidates by the candidate’s state
State
Candidates
Amount
California
20
$77K
North Carolina
8
$45K
Louisiana
6
$28.5K
New York
10
$28.5K
Florida
10
$28K
Oklahoma
6
$22.5K
Indiana
5
$21.5K
Virginia
4
$21K
The largest 8 of 47 states.
Recipients 211
Show candidate activity and the money network
Candidate and election activity as the recipients filed it
Deborah Ross2 receipts, latest Mar 25, 2026Deborah Ross for Congress · H0NC02125$10K
Kevin Mullin2 receipts, latest Mar 25, 2026Kevin Mullin for Congress · H2CA14162$10K
Mark Robert Warner2 receipts, latest Mar 25, 2026Friends of Mark Warner · S6VA00093$10K
S. Brett Brett Guthrie2 receipts, latest Mar 25, 2026Guthrie for Congress · H8KY02031$10K
Richard L. Hudson Jr.2 receipts, latest Mar 25, 2026Hudson for Congress · H2NC08185$10K
Candidate contribution rows come from candidate committee Schedule A filings, the same rows the party chart above counts.
Committee money network
Money moving between this committee and other committees, matched on FEC committee ID rather than the name each filing was typed under. Both sides exclude memo entries. The figures here count each committee once, from the itemized transfers read for this section, so they will not match the payment counts under Who this PAC gave to.
Committees funding this one
Committees that reported giving to this one on their own Schedule A filings, grouped by the giver’s committee ID.
No committee-to-committee receipts were itemized this cycle.
Committees this one funds
Disbursements this committee itemized to another committee: candidate contributions, party transfers and payments alike, not contributions only.
Where the money came from $685,570 reported receipts
Tap a row with to see who gave.
Itemized (over $200)Donors who have given more than $200 this cycle, so the FEC itemizes (names) them.$574,88084%
Largest donors
Chan Chea2 contributions, latest Jan 8, 2026 · SVP, TAX · GILEAD SCIENCES, INC. · FOSTER CITY, CA$10,000
Johanna Mercier2 contributions, latest Feb 4, 2026 · CHIEF COMMERCIAL & CORPORATE AFFAIRS O · GILEAD SCIENCES, INC. · FOSTER CITY, CA$10,000
Aquarius Gilmer40 contributions, latest Oct 2, 2026 · SR SENIOR DIRECTOR, BUSINESS STRATEGY · GILEAD SCIENCES, INC. · FOSTER CITY, CA$7,681
Anna Griffin40 contributions, latest Oct 2, 2026 · EXEC DIRECTOR, GOVERNMENT AFFAIRS · GILEAD SCIENCES, INC. · FOSTER CITY, CA$7,681
Kristina Hermach40 contributions, latest Oct 2, 2026 · SR DIRECTOR, GOVERNMENT AFFAIRS · GILEAD SCIENCES, INC. · FOSTER CITY, CA$7,681
Daniel O'Day40 contributions, latest Oct 2, 2026 · CHAIRMAN & CEO · GILEAD SCIENCES, INC. · FOSTER CITY, CA$7,681
Scott Wolff40 contributions, latest Oct 2, 2026 · DIRECTOR, OPERATIONAL EXCELLENCE · KITE PHARMA, INC. · FOSTER CITY, CA$7,681
Flavius Martin40 contributions, latest Oct 2, 2026 · EVP, RESEARCH · GILEAD SCIENCES, INC. · FOSTER CITY, CA$7,641
Nathaniel Sillin40 contributions, latest Oct 2, 2026 · SR DIRECTOR, PUBLIC AFFAIRS · GILEAD SCIENCES, INC. · FOSTER CITY, CA$7,400
Jared Baeten38 contributions, latest Oct 2, 2026 · SVP, VIROLOGY · GILEAD SCIENCES, INC. · FOSTER CITY, CA$7,297
Camille M. Alexander38 contributions, latest Oct 2, 2026 · VP, TOTAL REWARDS · GILEAD SCIENCES, INC. · FOSTER CITY, CA$7,296
Manendiu Anne Bazile38 contributions, latest Oct 2, 2026 · EXEC DIRECTOR, GOVERNMENT AFFAIRS · GILEAD SCIENCES, INC. · FOSTER CITY, CA$7,296
A donor who gave several times appears once. The 12 largest donors by total given are listed. In all, 5,867 itemized contributions were filed this cycle, totaling $574.5K. FEC contributor lists are public records and cannot be used for commercial solicitation.
Unitemized ($200 or less)Donors who have given $200 or less this cycle, so the FEC does not itemize (name) them.$88,19013%
Refunds and rebatesMoney coming back to the committee: rebates and refunds of what it spent, contributions it made that were returned, and loans it made that were repaid.$22,5003.3%
Total reported receipts $685,570
Every dollar the committee reported receiving this cycle, split by the source the FEC filing attributes it to. FEC filings through Oct 14, 2026.
Who donated: where they live, their employers and jobs
Where the donors live $574,715 placed by state
Loading the map
Tap or hover over a state, or focus the map and use the arrow keys, to read its total. Ctrl or ⌘ and scroll to zoom.
under $23K
$23K+
$92K+
$206.9K+
$367.8K+
none
Top states
Top donor states
Name
Amount
California5,868 contributions · 100%
$574,715
By the state each contributor wrote on the filing. The FEC aggregates every Schedule A line together, so one committee or organization transfer can account for a whole state. Contributors who have given $200 or less this cycle are not itemized and cannot be placed on a map. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total.
Donors’ employers as filed
Donors’ employers
Employer as filed
Amount
Gilead Sciences INC5,033 contributions · 87% of ranked
$497,303
Kite Pharma INC834 contributions · 13% of ranked
$77,220
A further $192 came from donors whose answer names no employer (blank), so it is not ranked. Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($88,190) are not itemized, so no employer or occupation is filed for them.
Donors’ occupations
SpendingWhere does the money go?
How the spending splits $847,704 reported
Tap a row with to see who was paid.
Contributions to candidates and other committeesMoney given to federal candidates, party committees and other PACs.$799,50094%
Other disbursementsEverything the committee reports outside the lines above.$47,0005.5%
Paid to
Operating expendituresThe committee's own running costs.$1,0120.1%
Paid to
Wells Fargo Bank3 payments · latest May 12, 2025 · BANK FEES$1,012
Contribution refundsMoney returned to the people and committees that gave it.$192<0.1%
Total reported disbursements $847,704
Every dollar this committee reported spending this cycle, split by the lines it reports against. Open a line to see who was actually paid on it. FEC filings through Oct 14, 2026.
What the payments were for $835,012 itemized
Tap a row with to see what was paid for.
Given to othersContributions to other candidates, party committees, and PACs.$841,50099.9%
Filed as
CONTRIBUTION$787,000
NONFEDERAL CONTRIBUTION$54,500
Paid to
New Democrat Coalition Action Fund$10,000
House Conservatives Fund$10,000
Blue HEN Federal PAC$10,000
CHC Bold PAC$10,000
Congressional Black Caucus PAC$10,000
Equality PAC$10,000
Taxes, fees, and bank chargesPayroll and income taxes, filing fees, bank and merchant processing charges.$1,0120.1%
Filed as
BANK FEES$1,012
Paid to
Wells Fargo Bank$1,012
Total itemized disbursements $835,012
Every itemized payment the committee reported this cycle, sorted by what it said each one was for. The categories are ours; the wording they are matched against is the committee’s own. Open a category to read the filed descriptions and who was paid. FEC filings through Oct 14, 2026.
All 435 itemized payments filed this cycle. Spending below the itemization threshold is not filed line by line.
Spending over time
$881.7K spent from Jan 2025 to Oct 2026. Most in one report: $201.5K, March 2026.
$881.7K
Jan 2025Oct 2026
The running total of what the committee’s FEC reports say it spent, independent expenditures included, with a point at the end of each report. The line is straight between reports because a report gives one total for its whole period.
Each report’s total
Oct 1 – Oct 14, 2026$0
September 2026$107,000
August 2026$0
July 2026$8,000
June 2026$123,000
May 2026$0
April 2026$0
March 2026$201,500
February 2026$1,500
January 2026$192
December 2025$141,000
November 2025$0
October 2025$0
September 2025$93,500
August 2025$0
July 2025$0
June 2025$67,000
May 2025$457
April 2025$555
March 2025$138,000
February 2025$0
January 2025$0
Show other payments: transfers, refunds and the rest
Besides giving through its PAC, Gilead Sciences Inc pays lobbyists to press Congress and federal agencies. Each quarter it, or a firm it hires, files a public report under the Lobbying Disclosure Act saying which topics it worked on, what it spent, and whom it contacted. This is what those reports say.
Spent on lobbying in 2026
$13.7M
Quarterly reports read
43
Bills it named
3
Topics it lobbied on
Each report files its work under official topics. The bar shows how often each topic came up across the reports; open one to read what was filed under it. Naming a bill says the organization lobbied on it, not which side it took.
Health Issuesin 34 report entries
In its own words
Advocate on drug pricing proposals.
Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization;
PEPFAR;
HIV/AIDS access to care, research, testing and treatment.
Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio.
Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer.
Advocate in favor of 340B program reforms and changes.
Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
Domestic and global drug pricing proposals.
International trade and protection of intellectual property.
Global supply chain issues.
Proposals to expand access to HIV treatment and prevention therapies.
Coverage and reimbursement policy for Hepatitis C, HIV and cancer.
Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. 340B program reforms and changes.
Issues related to healthcare, including improving patient access to advanced immunology therapies;
Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid;
Issues related to funding for HIV and HCV screening, linkage to care and treatment;
Issues related to breast cancer screening.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169);
Issues related to HIV;
Issues related to the implementation of the American Relief Act of 2025 (PL 118-158);
Issues related to the One Big Beautiful Bill Act (PL 119-21).
Prescription drug payment reform. Supply Chain. 340B Program. Implementation of Inflation Reduction Act of 2022. General HIV policy. Prescrption drug pricing policy.
IRA, pharmaceuticals access and affordability, drug pricing in federal programs, HCV screening, drug pricing and access, HIV, oncology, PAHPA reauthorization
Offices it contacted
HOUSE OF REPRESENTATIVES
SENATE
Health & Human Services, Dept of (HHS)
Executive Office of the President (EOP)
White House Office
Centers For Disease Control & Prevention (CDC)
Centers For Medicare and Medicaid Services (CMS)
Commerce, Dept of (DOC)
and 5 more offices
Food & Drug Administration (FDA)
Natl Institutes of Health (NIH)
State, Dept of (DOS)
U.S. Trade Representative (USTR)
Office of Management & Budget (OMB)
Medicare/Medicaidin 22 report entries · 3 bills named
In its own words
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022.
Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299).
Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Policies related to the Most Favored Nation Drug Pricing Model.
Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals.
HCV testing, screening and linkage to care programs.
Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign.
CMS rules, including those related to payments in Medicare, Medicaid drug rebates, and proposed CMMI demonstrations.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169);
Issues related to the implementation of the American Relief Act of 2025 (PL 118-158);
Issues related to the One Big Beautiful Bill Act (PL 119-21).
Budget/Appropriationsin 13 report entries
In its own words
Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations.
Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.
Issues related to pharmaceuticals and drug development.
Issues related to HIV prevention and procurement.
federal budget issues
Offices it contacted
HOUSE OF REPRESENTATIVES
SENATE
Office of Management & Budget (OMB)
Centers For Medicare and Medicaid Services (CMS)
Health & Human Services, Dept of (HHS)
White House Office
Executive Office of the President (EOP)
Taxation/Internal Revenue Codein 7 report entries
In its own words
Legislative and regulatory proposals to change international and domestic corporate tax law and policy.
Legislative services related to corporate and international tax matters.
Offices it contacted
HOUSE OF REPRESENTATIVES
SENATE
Commerce, Dept of (DOC)
Treasury, Dept of
Trade (domestic/foreign)in 5 report entries
In its own words
Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries.
Issues related to MFN pricing and trade
Offices it contacted
Commerce, Dept of (DOC)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
Patent & Trademark Office (PTO)
SENATE
State, Dept of (DOS)
U.S. Trade Representative (USTR)
White House Office
Copyright/Patent/Trademarkin 4 report entries
In its own words
Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding.
Offices it contacted
Commerce, Dept of (DOC)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
Patent & Trademark Office (PTO)
SENATE
U.S. Trade Representative (USTR)
Pharmacyin 3 report entries
In its own words
Issues related to drug pricing.
Offices it contacted
SENATE
Who did the lobbying
The organization’s own reports give its total lobbying costs, including any firms it hired; each firm reports what this client paid it.
Gilead Sciences, Inc.Its own staff · 4 reports$13.7M
Miller Strategies, LLCLobbying firm · 3 reports$450K
The Duberstein Group Inc.Lobbying firm · 3 reports$270K
B Hall Strategies, LLCLobbying firm · 3 reports$90K
Contributions on the LD-203 report
Reported twice a year by the lobbying filer. $271K is political giving that also appears in FEC filings. $32.5K is honorary, presidential-library and event money disclosed only here.
Rep. Brad Schneider$6.5K
House Conservatives Fund Leadership$5K
Members of the Congressional Black Caucus$5K
Members of the Congressional Hispanic Caucus$5K
Members of the LGBTQ Caucus$5K
Members of the Moderate Democrats Caucus$5K
Members of the New Democrats Caucus$5K
National Republican Senatorial Committee$5K
Rep. Brett Guthrie$5K
Rep. Deborah Ross$5K
Matched by name: these reports are filed for “GILEAD SCIENCES INC”, found by searching “GILEAD SCIENCES”. Lobbying and FEC records share no ID, so an organization that lobbies under another name is missed. Source: LDA.gov, accessed Nov 6, 2026. Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.
Gilead Sciences Inc Healthcare Policy PAC is registered with the Federal Election Commission as a PAC (qualified). It is a lobbyist/registrant PAC. Its FEC record names Gilead Sciences, Inc. as an affiliate. Official FEC summary: Federal Election Commission committee record.
Pages quoted 0 pages
No pages quoted
Nothing from this committee’s or its sponsor’s site is quoted yet.
Linked public records
No approved organization identity yet
The official FEC committee record remains available under Filings.
$797K across 213 recipient committees, or 94% of everything this committee reports spending. The largest 12 are shown.
Built from FEC Schedule A and Schedule B filings for the selected cycle. A committee only appears here if the money was itemized under its FEC committee ID.
as filed
Donors’ occupations
Occupation as filed
Amount
SR Director Government Affairs255 contributions · 5.1% of ranked
$29,057
Exec Director Government Affairs200 contributions · 4.6% of ranked
$26,147
National Account Director290 contributions · 2.9% of ranked
$16,435
VP Government Affairs119 contributions · 2.6% of ranked
$15,120
Director Sales144 contributions · 2.2% of ranked
$12,777
SR Director Public Affairs63 contributions · 2.2% of ranked
$12,460
SR Director Marketing65 contributions · 1.7% of ranked
$9,812
Director Government Affairs144 contributions · 1.5% of ranked
$8,475
A further $192 came from donors whose answer names no occupation (blank), so it is not ranked. Ranked from the largest 200 of 201 occupation spellings filed; each share is of the money in those. Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($88,190) are not itemized, so no employer or occupation is filed for them.
The people, firms and committees paid the most, across every kind of payment. Each share is of everything the committee reported spending this cycle, not only the itemized payments above. A payee that is itself a committee links to its own profile.
Byron Donalds for Governor1 payment, latest Jul 9, 2026NONFEDERAL CONTRIBUTION$3K
Texas House Republican Caucus PAC3 payments, latest Feb 20, 2026NONFEDERAL CONTRIBUTION$2.5K
Matt Hall for State Representative1 payment, latest Dec 22, 2025NONFEDERAL CONTRIBUTION$2.5K
Texas Legislative Black Caucus3 payments, latest Feb 20, 2026NONFEDERAL CONTRIBUTION$2.5K
Texas Senate Democratic Caucus3 payments, latest Feb 20, 2026NONFEDERAL CONTRIBUTION$2K
Transfers, refunds, and everything else the committee itemized outside candidate giving. 55 payments totaling $47K.
Coverage and reimbursement policy for HCV and HIV portfolios.
Issues pertaining to the six protected classes.
Drug pricing legislation- part D redesign.
Issues related to Medicaid drug rebate program.
Monitoring CMMI demonstrations
Implementation H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing.
Implementation H.R.5376 - Inflation Reduction Act of 2022. Issues around drug pricing.